Shop Now Contact

Anti-Human EGFR (Cetuximab Biosimilar)

Cat # Size Price Quantity
5014011 mg$190
5014025 mg$500
50140320 mg$1390

  Bulk/Custom

Product Details

CloneCetuximab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionCetuximab Biosimilar, Human EGFR Monoclonal Antibody
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman EGFR / ErbB-1
Clone NumberC225
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
Maximal Shelf Life12 months
SynonymsErbB1, HER1
Target NameEGFR, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, HER1
Antibody TypeRecombinant
Research AreasCancer Marker, Epithelial cells
See All FormatsClone Cetuximab

Background Information

Cetuximab is a chimeric monoclonal antibody designed to specifically target the extracellular domain of the epidermal growth factor receptor (EGFR), also known as ErbB1 or HER1. Structurally, Cetuximab belongs to the immunoglobulin G1 (IgG1) subclass and is composed of two identical heavy chains and two identical light chains connected by disulfide bonds, creating a Y-shaped molecule with a molecular weight of approximately 152 kilodaltons (kDa). The molecule combines murine variable regions responsible for antigen recognition with human constant regions, resulting in a chimeric structure that preserves specificity while improving structural stability and compatibility with human immune components. It is produced using recombinant DNA technology in mammalian expression systems, typically in murine myeloma cells.

The variable regions of the heavy (VH) and light (VL) chains contain complementarity-determining regions (CDRs) that define the antibody’s epitope specificity. These CDRs bind with high affinity to the extracellular ligand-binding domain of EGFR, preventing the natural ligands, epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), from interacting with the receptor. This blockade inhibits receptor dimerization and autophosphorylation at key tyrosine residues within the intracellular kinase domain, thereby disrupting downstream signaling cascades such as RAS-RAF-MAPK and PI3K-AKT pathways. These pathways are critical for the regulation of cellular proliferation, differentiation, and survival, making Cetuximab a valuable molecular tool for investigating growth factor signaling networks in experimental systems.

The Fc region of Cetuximab, derived from the human IgG1 isotype, contributes to its biophysical stability and extended serum half-life through interaction with neonatal Fc receptors (FcRn). It also retains the potential for effector functions via binding to Fc gamma receptors (FcγRs), enabling engagement with immune effector cells in research contexts.

Data Sheets

Anti-Human EGFR (Cetuximab Biosimilar) TDS

Related Protocols

Flow Cytometry Protocol

Related Products

Anti-Human EGFR Antibody, Clone 528

Anti-Human EGFR (Matuzumab Biosimilar), Clone Matuzumab

Anti-Human EGFR (Nimotuzumab Biosimilar), Clone Nimotuzumab

Anti-Human EGFR (Panitumumab Biosimilar), Clone Panitumumab

Biotin Anti-Human EGFR Antibody, Clone 528

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.